Stunning divergence in equities is a short-term opportunity Stunning divergence in equities is a short-term opportunity Stunning divergence in equities is a short-term opportunity

Stunning divergence in equities is a short-term opportunity

Equities 4 minutes to read
Peter Garnry

Head of Equity Strategy

Summary:  Travel stocks are soaring on good Omicron news and a quicker path to normalisation and the broader commodity sector is still favoured as investors are adding protection against inflation to their portfolios. The flipside is a bloodbath in speculative bubble stocks and themes such as NextGen Medicine and E-commerce. The divergence in just two trading session is stunningly 9.1%-point between the travel and bubble stocks baskets. While there are many arguments for why bubble stocks could fall more, we think the selloff will soon turn into a "buying-the-dip" situation with the market betting on bubble stocks going into the earnings season on the notion that this part of the market will deliver growth surprises.

Speculative growth stocks are continuing their 2021 descent

We are only two full trading sessions into the new year and we are already observing a 9.1%-point difference in performance between the travel basket, helped by the good news on the Omicron variant, and bubble stocks which suffering from the latest move higher in the US 10-year yield and investors continuing their rotating out of speculative growth and adding inflation hedges such as mega caps, financials, energy and mining.

While we think that a better balance between the physical and the online is warranted in the portfolio as inflation will run higher for longer due to physical constraints across energy and metals during the green transformation. But short-term we think a tactical trading opportunity is emerging as many bubble stocks will continue to show high revenue growth, whether they can deliver on operating margin is a different story, and that they will be bought back again by investors. The next couple of weeks could be tough for speculative bubble stocks, but our thinking is that investors will pick them up ahead of the earnings season betting on revenue surprises lifting share price against deteriorating expectations.

Bubble stocks basket

NameMkt Cap (USD mn.)12M Fwd EPS12M Fwd EV/SalesDiff to PT (%)5yr return (%)YTD return (%)
Kuaishou Technology213,499-0.8516.295.5NA-6.2
Sea Ltd140,384-1.2617.3101.5NA-11.6
Airbnb Inc130,635-1.3128.114.0NA2.6
NIO Inc94,795-1.5918.089.8NA-0.3
Snowflake Inc84,570-0.8771.525.7NA-6.9
DoorDash Inc67,743-0.1917.671.9NA-8.7
Roku Inc59,111-0.2623.160.9NA-2.4
Bilibili Inc51,601-4.7618.2159.8NA-12.9
Teladoc Health Inc41,124-0.3020.372.3452.7-0.4
XPeng Inc37,228-2.4115.032.2NA-5.4
Affirm Holdings Inc34,499-0.8939.782.5NA-15.1
BeiGene Ltd34,490-9.7835.871.1699.2-9.1
Unity Software Inc34,299-0.3532.734.5NA-9.3
Plug Power Inc32,156-0.1868.175.52,152.0-0.3
Seagen Inc31,016-0.1115.923.3165.3-1.2
Cloudflare Inc28,050-0.0846.187.0NA-12.6
Splunk Inc27,486-0.2110.844.5106.20.1
MongoDB Inc25,201-0.9834.120.5NA-12.1
Exact Sciences Corp24,752-1.1413.360.7429.92.8
Gaotu Techedu Inc24,455-3.3411.8NANANA
Farfetch Ltd23,465-0.6610.349.1NA-1.1
DraftKings Inc23,186-1.1626.5118.3NA-3.1
GDS Holdings Ltd20,998-0.1518.695.9389.5-13.0
10X Genomics Inc20,458-0.3238.941.5NA-5.1
Argenx SE19,397-10.72105.27.71,718.1-3.9
Alnylam Pharmaceuticals Inc19,214-4.7721.025.3291.3-2.6
Ping An Healthcare and Technology Co Ltd18,942-0.9111.6115.1NA-10.2
Innovent Biologics Inc18,305-0.6124.0140.5NA-17.2
Guardant Health Inc16,826-1.5040.563.9NA-2.0
Zai Lab Ltd15,781-2.5287.5163.3NA-12.1
Kingsoft Cloud Holdings Ltd15,710-2.569.6145.9NA-12.4
Yatsen Holding Ltd15,665-1.1710.766.0NA-7.9
Oak Street Health Inc15,461-0.4611.167.9NA-3.2 Inc15,370-0.7969.668.4NA-1.4 Holdings Inc15,319-0.1957.465.3NA-12.3
Canopy Growth Corp15,279-0.9024.
Appian Corp15,229-0.4043.357.5NA1.1
Avalara Inc14,770-0.1621.370.7NA-5.9
Elastic NV14,429-0.4420.650.1NA-5.5
Wolfspeed Inc14,240-0.5921.3NANANA
Aggregate / median1,565,14121.367.0409.7-5.5
Source: Bloomberg and Saxo Group

The market is betting on a totally different car industry

As a follow up to yesterday’s equity note, we extended our commentary on the EV battle in today’s podcast. We failed to cover all our thoughts because we have to be conscious of time, so we expanded further on our thinking in this Twitter thread. At any case, the EV battle this year is one of the most interesting to watch and a defining moment for the car industry. A lot of market value is at risk this year. We forgot in our Twitter thread to elaborate a bit on the car as a platform. The idea for the bulls on Tesla is that 1) the company takes 25% global market share, and 2) cars will become a major digital platform in which you can sell software services on. In that scenario, Tesla could be extremely profitable, but the path to the endpoint is not without risk and while we have seen Volkswagen having difficulties ramping up production to beat Tesla, we do not yet know the dynamics of the remaining large players (Ford, GM, Toyota etc.) entering the EV race at full force.


The Saxo Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (
- Full disclaimer (

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments. Saxo does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo or its affiliates.

Saxo Capital Markets HK Limited
19th Floor
Shanghai Commercial Bank Tower
12 Queen’s Road Central
Hong Kong

Contact Saxo

Select region

Hong Kong S.A.R
Hong Kong S.A.R

Saxo Capital Markets HK Limited (“Saxo”) is a company authorised and regulated by the Securities and Futures Commission of Hong Kong. Saxo holds a Type 1 Regulated Activity (Dealing in Securities); Type 2 Regulated Activity (Dealing in Futures Contract); Type 3 Regulated Activity (Leveraged Foreign Exchange Trading); Type 4 Regulated Activity (Advising on Securities) and Type 9 Regulated Activity (Asset Management) licenses (CE No. AVD061). Registered address: 19th Floor, Shanghai Commercial Bank Tower, 12 Queen’s Road Central, Hong Kong.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Trading in leveraged products may result in your losses exceeding your initial deposits. Saxo does not provide financial advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo does not take into account an individual’s needs, objectives or financial situation. Please click here to view the relevant risk disclosure statements.

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit

The information or the products and services referred to on this site may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and services offered on this website are not directed at, or intended for distribution to or use by, any person or entity residing in the United States and Japan. Please click here to view our full disclaimer.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc. Android is a trademark of Google Inc.